Today on DrugResearcher.com   Synta reawakens 40 year old anticancer mechanism Personalised medicine boosted by new cancer target Pfizer's Nigerian court trial over Trovan scandal to kick off Novartis weighs up label-free HTS for drug discovery Novartis diabetes drug gets thumbs up in EU

Related Industry News   DSM accelerates its new image Batches binned in new production tech link up Genentech could be in the center of steroid bust No wobbles for jelly nasal spray vaccine

Breaking News on Drug Discovery
Daily  Monday 01 October 2007		Forward to a colleague

	Product Brochure Unique Process technology for drying very small quantities of API ProCepT's R&D Drying Technology for small quantities of API; SPRAY DRYING - NUTSCHE FILTER DRYING - AGITATED VACUUM DRYING - MICROWAVE DRYING. Fully instrumented and automated for Maximum of process knowledge with Minimum of API in a Minimum of time! Make use of the ProCepT lab... Click Here Access Full Stories Synta reawakens 40 year old anticancer mechanism Although it is over forty years since scientists realised cancer cells don't have the anti-oxidant protective capabilities of normal cells, it seems that only one pharma company has developed a drug to exploit... Read Personalised medicine boosted by new cancer target A new target for anticancer drugs is over expressed in cancer cells to a much greater extent than other oncogenes, boosting the prospects of personalised therapy in the field... Read Pfizer's Nigerian court trial over Trovan scandal to kick off Pfizer will appear this week in a Nigerian court to face allegations that it caused the death of Nigerian children over a decade ago when it conducted a clinical trial of its meningitis drug Trovan (trovafloxacin)... Read Novartis weighs up label-free HTS for drug discovery Researchers from Novartis have published results using high-throughput screening (HTS) mass spectrometry (MS) techniques for the identification of enzyme inhibitors... Read Novartis diabetes drug gets thumbs up in EU Novartis's potential Type II diabetes blockbuster has been given the green light in the EU after receiving approval... Read
	All News Headlines for: October | September | August
	Application Notes Separation of polar compounds A Mini-tutorial to HILIC The ZIC®-HILIC column is the ideal choice for separation of polar and hydrophilic compounds. Amino acids, bases, peptides, carbohydrates, plant extracts and other polar compounds have good retention on the column from SeQuant - "The Number One in HILIC"... Click Here
	Related Industry News DSM accelerates its new image DSM has announced the conclusions for the company's complete overhaul as it accelerates the shift to a life sciences and materials sciences company... Read Batches binned in new production tech link up Novartis has hooked up with the Massachusetts Institute of Technology (MIT) to fund a project aimed at 'revolutionising' pharmaceutical manufacturing and doing away with traditional batch-based production techniques... Read Genentech could be in the center of steroid bust Genentech is remaining tight-lipped regarding an alleged security breach at its South San Francisco facility with alleged links to a steroid drug bust, last week... Read No wobbles for jelly nasal spray vaccine It is not the same as jellied pig's trotters, but a jelly nose has the 'exciting potential' to be the next weapon in the arsenal against pandemic flu... Read Inside India: special series Clinical trials in India: 'The wind is blowing' An industry veteran gives Outsourcing-Pharma.com an update on the state of the contract research organisation (CRO) industry in India. Read Product Brochure A revolution in Sales Lead Generation! - Free Download Promote your products and technology towards our readers, and we'll build a detailed profile of each person who reads your presentation document... Download our FREE Smart Lead Generation brochure now!... Click Here Previous Headlines GlaxoSmithKline cancer vaccine 'impressive' GlaxoSmithKline (GSK) has taken a step closer to a true targeted cancer therapy, and its vaccine, which 'educates' the immune system to kill tumour cells, has showed 'impressive' results in its latest clinical... Read AZ hoping its prostate cancer drug will succeed where Abbott's failed After decades of limited options and false hopes, prostate cancer sufferers will be hoping AstraZeneca's (AZ) new drug can succeed where Abbott's failed... Read EU to fund stem cell assay development collaboration Stem Cell Sciences (SCS) has received a €2.4m boost from the European Union (EU) for its new drug screening development programme using neutral stem cells... Read Drugs moving into the clinic: 29 The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators... Read AstraZeneca teams up to fight Japan's drug lag AstraZeneca has teamed up with a Japanese university to co-conduct clinical trials in an effort to tackle Japan's so-called 'drug lag'... Read Product Information - brochures, Web centers Separation of polar compounds - Application Notes Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com